Cerus says Phase 3 RedeS trial met primary endpoint; INTERCEPT red blood cells non-inferior to conventional transfusions

Cerus said its Phase 3 RedeS trial met its primary endpoint, showing pathogen-reduced INTERCEPT red blood cells were non-inferior to conventional transfusions.

Detected & updated continuously · Source: Nebula